Demographics, Operative Characteristics, and Follow-up
death, breast implant
SQUAMOUS CELL CARCINOMA, ANAPLASTIC LARGE CELL LYMPHOMA, COMPLICATIONS
A total of 287 females received at least 1 MemoryGel Xtra breast implant in the study, including 151 primary augmentation, 76 revisional augmentation, 44 primary reconstruction, and 16 revisional reconstruction patients. Both smooth and textured Siltex devices were included, although approximately 95% of the devices were smooth. All of these participants underwent implant surgery at least 3 years ago. Follow-up at the 3-year time point was 81.1% across all cohorts with the MemoryGel Xtra implants. To present a snapshot of complications that surgeons and patients can expect with MemoryGel Xtra at 3 years after implantation, data collected beyond 3-year follow-up has been excluded, other than reports of death, BIA-ALCL (breast implant–associated anaplastic large cell lymphoma), or SCC (squamous cell carcinoma). The median age (range) for each cohort was as follows: primary augmentation 34.0 (20.4-66.8), revisional augmentation 43.3 (26.0-76.5), primary reconstruction 48.0 (23.9-72.7), and revisional reconstruction 53.6 (31.6-67.7). Demographic characteristics for the study participants who received MemoryGel Xtra implants are provided in Demographic Characteristics
Operative Characteristics and Follow-up